Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? by Ferrari, S. M. et al.
Review Article
Immunomodulation of CXCL10 Secretion by Hepatitis C Virus:
Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
Silvia Martina Ferrari,1 Poupak Fallahi,2 Ilaria Ruffilli,1 Giusy Elia,1 Francesca Ragusa,1
Sabrina Rosaria Paparo,1 Armando Patrizio,1 Valeria Mazzi,1 Michele Colaci ,3
Dilia Giuggioli,4 Clodoveo Ferri,4 and Alessandro Antonelli 1
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
2Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
3Internal Medicine Unit, Cannizzaro Hospital, Department of Clinical and Experimental Medicine, University of Catania,
Catania, Italy
4Rheumatology Unit, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy
Correspondence should be addressed to Alessandro Antonelli; alessandro.antonelli@med.unipi.it
Received 15 February 2019; Revised 19 April 2019; Accepted 30 April 2019; Published 8 August 2019
Academic Editor: Peirong Jiao
Copyright © 2019 Silvia Martina Ferrari et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Chemokine (C-X-C motif) ligand (CXCL)10 and other CXCR3 chemokines are involved in the pathogenesis of acute and “chronic
hepatitis C virus (HCV) infection” (CHC). Here, we review the scientific literature about HCV and CXCL10. The combination of
circulating CXCL10 and single nucleotide polymorphisms (SNPs) in IL-28B can identify patients with acute HCV infection most
likely to undergo spontaneous HCV clearance and those in need of early antiviral therapy. In CHC, the HCV and intrahepatic
interferon- (IFN-) γ drive a raised CXCL10 expression by sinusoidal endothelium and hepatocytes, thereby inducing the
recruitment of CXCR3-expressing T cells into the liver; thus, CXCL10 plays an important role in the development of
necroinflammation and fibrosis. Increased CXCL10 was significantly associated with the presence of active vasculitis in HCV-
associated cryoglobulinemia, or with autoimmune thyroiditis in CHC. Pretreatment CXCL10 levels are predictive of early
virological response and sustained virological response (SVR) to IFN-α and ribavirin and may be useful in the evaluation of
candidates for therapy. The occurrence of SNPs adjacent to IL-28B (rs12979860, rs12980275, and rs8099917), and CXCL10
below 150 pg/mL, independently predicted the first phase viral decline and rapid virological response, which in turn
independently predicted SVR. Directly acting antiviral agents-mediated clearance of HCV is associated with the loss of
intrahepatic immune activation by IFN-α, associated by decreased levels of CXCL10. In conclusion, CXCL10 is an important
marker of HCV clearance and successful therapy in CHC patients. Whether CXCL10 is a novel therapeutic target in CHC will
be evaluated.
1. Introduction
Hepatitis C is an infectious disease caused by the hepatitis
C virus (HCV), affecting 150–200 million people world-
wide [1]. Hepatitis C infection causes acute symptoms in
15% of cases. The infection resolves spontaneously in
10% of patients (more frequently in young and females)
[2]. Approximately 85% of those HCV-exposed develop a
chronic infection [3, 4]. HCV causes 27% of cirrhosis
cases and 25% of hepatocellular carcinoma (HCC), world-
wide [5–7].
About 38–76% of CHC patients develop at least one
extrahepatic manifestation (EHM) [8]. The term “HCV syn-
drome” involves hepatic and extrahepatic disorders, and
among them, mixed cryoglobulinemic vasculitis can be con-
sidered the pathophysiological prototype [9], involving vari-
ous organs and systems (joints, kidney, nervous system, skin,
and eyes). The infected extrahepatic tissues can function as a
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reservoir for HCV [9] that replicates and expresses viral
proteins in extrahepatic tissues, contributing to EHMs.
HCV avoids immune elimination, causing the accumula-
tion of circulating immunocomplexes, and autoimmune
phenomena [10].
EHMs include autoimmune disorders [11], such as MC
[12] and Sjogren’s syndrome, and endocrinological disor-
ders, such as autoimmune thyroid disorders and type 2 dia-
betes [13], and range from mild or moderate manifestations
(peripheral neuropathy, arthralgia, and sicca syndrome) to
severe, life-threatening complications (neoplastic conditions
and vasculitis) [14, 15].
In HCV infection, cytokines and chemokines take part in
viral control and liver damage. Chemokine (C-X-C motif)
ligand (CXCL)10 and the other CXCR3 chemokines partici-
pate in the pathogenesis of acute and “chronic hepatitis C
virus (HCV) infection” (CHC).
2. Cytokines and Chemokines
Cytokines are small proteins, secreted by different types of
cells: fibroblasts, immune cells (macrophages, B lympho-
cytes, and T lymphocytes), endothelial cells, and different
epithelial cells. Upon binding to specific receptors, cytokines
modulate the balance between cell-based and humoral
immune responses and have a key role in host responses to
infection, inflammation, immune responses, trauma, cancer,
and sepsis [16, 17].
Chemokines are chemotactic cytokines of about 8-10 kDa
in size. On the basis of the presence of 4 cysteine residues in
conserved locations, chemokines are classified into 4 subfam-
ilies: CXC (α), CC (β), C (γ), and CX3C (δ). Their receptors
are CXCR, CCR, CR, and CX3CR, respectively.
IFN-γ-induced protein 10 (IP-10)/chemokine (C-X-C
motif) ligand (CXCL)10 belongs to the ELR−CXC chemo-
kine family [18], and it is secreted upon IFN-γ stimulation
by different cell types (endothelial cells, keratinocytes, fibro-
blasts, monocytes, and T lymphocytes) [19]; also, proinflam-
matory cytokines (IFN-α, IFN-β, and TNF-α [20, 21]) are
able to induce its secretion.
CXCL10 exerts its biological effects principally through
CXCR3 [22], and it behaves as a chemoattractant for leuko-
cytes, particularly Th1 lymphocytes [23].
The determination of high CXCL10 levels in peripheral
liquids is believed to be a marker of host Th1-orientated
immune response. Activated Th1 lymphocytes cause an
increased IFN-γ and TNF-α production that stimulates the
target cells to secrete CXCL10, thus perpetuating the immune
cascade [24, 25].
An elevated tissue and/or cellular expression of CXCL10
is shown in organ-specific autoimmune diseases (including
type 1 diabetes [26], Graves’ disease [27] or Graves’ ophthal-
mopathy [27], and AT [28–30]) or systemic rheumatological
disorders (systemic lupus erythematosus, rheumatoid arthri-
tis, systemic sclerosis [31–34], psoriasis [31] or psoriatic
arthritis [35], and sarcoidosis [31, 36]).
Different neoplastic disorders show the involvement of
the Th1 immune response [37–41], too.
Moreover, CXCL10 is involved in the pathogenesis and
progression of infectious diseases [42] (i.e., Mycobacterium
tuberculosis [43]) or HCV-related autoimmune disorders
[10, 15, 44–46], sepsis [47], or HIV [48].
Here, we review the scientific literature about HCV infec-
tion and CXCL10 [given the complexity of the published data
on CXCL10 with other infections, the coinfections (for exam-
ple, HCV/HIV coinfection) will be excluded].
3. CXCL10 and Acute HCV Infection (Table 1)
During acute HCV infection, CXCL9-10-11 induction
started 38-53 days and peaked 72-83 days after virus acquisi-
tion; a similar pattern was observed for alanine aminotrans-
ferase (ALT) levels. The increase of CXCR3-associated
chemokines, in the late phase of acute HCV infection, leads
to hypothesize a role for cellular immune responses in che-
mokine secretion [49].
In six chimpanzees infected with HCV, chemokine
induction correlated with intrahepatic type I IFN responses
in vivo and was stopped by the neutralization of antibodies
against IFN-β in vitro [50].
A study evaluated IL-28B single nucleotide polymor-
phisms (SNPs) rs12979860 and rs8099917, together with
serum CXCL10 levels, reporting that the frequency of IL-
28B rs12979860 C/C genotype was higher in patients with
spontaneous clearance than those without [51]. The CXCL10
median level was lower among patients with acute HCV
infection and spontaneous clearance (764 pg/mL) than those
without spontaneous clearance (1481 pg/mL). Considering
also the data on CXCL10 levels, the capability of the IL-28B
rs12979860 C/C of identifying patients more prone to have
spontaneous clearance (83% of those who had a CXCL10
level < 540 pg/mL and 32% of whom with CXCL10 > 540
pg/mL) increased. Combining circulating CXCL10 and
SNPs in IL-28B, patients with acute HCV infection who
Table 1: CXCL10 and acute HCV infection.
CXCL10 and acute HCV infection References
Increase of CXCR3-associated chemokines, during the late phase of acute HCV infection [49]
An in vivo study showed that despite an early-stage induction of chemokines, the intrahepatic lymphocytic infiltrate increased
not earlier than 8 weeks after HCV infection
[50]
CXCL10 serum levels and SNPs in IL-28B can identify patients with acute hepatitis C who are more prone to undergo
spontaneous clearance and those in need of early antiviral therapy
[51]
Truncated CXCL10 is associated with failure to obtain spontaneous clearance of acute hepatitis C infection [54]
Both CXCR3 and CCR2 were overexpressed on HCV-specific CD8+CCR7+CD45RO+ (central memory) cells [55]
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are more prone to have clearance spontaneously, and those
who need an early antiviral therapy, can be identified
[51]. These results were confirmed by other studies [52, 53].
Moreover, truncated CXCL10 is associated with the lack
of spontaneous clearance of acute HCV infection, providing
evidence of chemokine antagonism during acute HCV infec-
tion [54].
The last study reported that CXCR3 and chemokine
receptor (CCR)2 were overexpressed on HCV-specific
CD8+CCR7+CD45RO+ (central memory) cells. These
results suggested that CXCR3-mediated signals accumulate
HCV-specific CD8+memory T cells in the infected liver [55].
4. CXCL10 and Chronic CHC (Table 2)
High levels of CXCR3 receptors are expressed by the lym-
phocytes that infiltrate a hepatitis C-infected liver [56].
CXCL10 and monokine-induced by IFN-γ (Mig)/CXCL9
are upregulated on sinusoidal endothelium. CXCL10 and
CXCL9 are secreted by human IFN-γ+TNF-α-stimulated
hepatic sinusoidal endothelial cells in vitro, suggesting
that in CHC the production of IFN-γ in the liver causes
the raised CXCL10 and CXCL9 expression and recruits
CXCR3-expressing T cells in the hepatic lobule [56].
CXCR3 ligands are responsible for regional localization
of specific lymphocyte subsets in the HCV-infected liver
[57–59].
Another paper showed that in CHC (but not in other
liver disorders), CXCL10 expression was highly correlated
with the total transcripts of IFN-γ [60].
HCV can induce CXCL10 in hepatocytes, taking part in
the pathogenesis of CHC [61].
Another paper reported that CXCL9 and CXCL10
expression in human hepatocyte-derived cells is upregulated
Table 2: CXCL10 and chronic CHC.
CXCL10 and chronic CHC References
The intrahepatic production of IFN-γ causes the raised CXCL10 and CXCL9 expression and recruits CXCR3-expressing
T cells in the hepatic lobule.
[56]
CXCR3 ligands are responsible for regional localization of specific lymphocyte subsets in the HCV-infected liver. [57]
Increased expression, in chronic HCV infection, of IFN-α/β-inducible antiviral MxA gene; gene encoding IFN-α/β-inducible
p44; gene encoding IFN-α/β/γ-inducible IFI-56K.
[58]
Hepatocytes in inflammatory areas produce CXCL10 either in autoimmune liver diseases or in chronic viral hepatitis. [59]
Hepatic inflammatory activity was associated more strongly with IFN-γ than with CXCL10. [60]
CXCL10 may be induced by HCV within hepatocytes, resulting to be an important factor in the pathogenesis of CHC. [61]
CXCL10 and CXCL9 gene expression in cultured human hepatocyte-derived cells is upregulated by NS5A and core
proteins, alone or in combination with cytokines.
[62]
Hepatocytes in CHC patients participate in CXCL10 production involving TLR2 and CD44. [65]
CXCL10 and its noncognate receptor, TLR4, are proapoptotic signaling cascades for hepatocytes during liver injury. [66]
Nonparenchymal hepatic cells and immune effector cells were recruited in the site of infection by CXCL10. These cells
by secreting type I, II, and III IFNs amplify CXCL10 response during the later stages of acute HCV infection.
[63]
Investigations about the mechanisms of CXCL10 induction in hepatocytes by several factors (such as NF-κB and IRF3).
Perpetual inflammation and viral persistence could be arisen because of viral proteins that antagonize with these factors
and then interfere with the induction of CXCL10.
[64]
In the first stage of liver fibrosis, the principal alterations in gene expression affected in particular the IFN-regulated
transcriptional network, such as IFN-α/β-inducible genes (STAT1, STAT2, ISGF3G/IRF9, IFI27, G1P3, G1P2, OAS2, andMX1)
and IFN-γ-inducible genes (CXCL9, CXCL10, and CXCL11).
[67]
CXCL10 mRNA expression levels were significantly associated with lobular necroinflammatory grade and HCV genotype 1. [68]
Patients with advanced fibrosis had significantly increased CXCL10 plasma levels. [69]
CXCR3 chemokines are the most strongly expressed chemokines in CHC and presumably have a key role in positioning
T cells in the liver.
[70, 71]
CXCL10 is an independent biomarker of the recurrence of significant fibrosis after liver transplantation for HCV infection. [72]
Studies reported that in CHC, CXCL10 can be considered a marker of liver fibrosis. [73–75]
HCV-induced CXCL10 can lead to a raised hepatocyte turnover and the development of cirrhosis, fibrosis, and HCC. [37]
Circulating CXCL10 in many HCV patients is enzymatically processed to produce a CXCL10 antagonist form,
introducing a role for chemokine antagonism during HCV infection.
[76–78]
Serum CXCL10 levels were significantly lower in patients with seronegative occult HCV infection than in patients
with chronic hepatitis C.
[79]
The single nucleotide polymorphism CXCL10 rs1439490 G/G is positively associated with occult HCV infection in HCV. [80]
High CXCL10 and TNF-α serum levels were observed in patients with hepatitis C-associated cryoglobulinemia (MC+HCV),
and in particular, increased CXCL10 levels were significantly associated with the presence of active vasculitis.
[81]
In mixed cryoglobulinemia patients, circulating CXCL10 was higher in those with associated autoimmune thyroiditis. [82]
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by NS5A and core proteins, alone, or in combination, with
cytokines [62].
Other papers confirmed the induction of CXCL10 release
by HCV in hepatocytes [63, 64], involving TLR2 and CD44
[65]. CXCL10 and its noncognate receptor, TLR4, induce a
proapoptotic signaling cascade for hepatocytes during liver
injury [66].
To understand the molecular pathogenesis of the first
stage of liver fibrosis (F1-CH-C) in hepatitis C patients, the
mRNA expression of 240 selected genes in liver tissue with
F1-CH-C was evaluated, compared to the normal liver (NL)
[67]. The principal alterations in gene expression affected
especially the IFN-regulated transcriptional network, such
as IFN-α/β-inducible genes (STAT1, STAT2, etc.) and IFN-
γ-inducible genes (CXCL9, CXCL10, and CXCL11) [67].
Among the IFN-inducible genes, from fibrosis stage F1 to
fibrosis stage F4 (in particular the transition F1-CH-C to
F2-CH-C), only the mRNA levels of IFN-γ-inducible genes
increased at the limit of the statistical significance, while
the expression of the IFN-α/β-inducible genes did not
change [67].
A further study showed that in the liver CXCL10 mRNA
expression was significantly associated with lobular necroin-
flammatory grade and HCV genotype 1 [68]. CXCL10
expression increased strongly with a higher stage of fibrosis
compared to CXCL9 and CXCL11. The reported data
suggested that in CHC, CXCL10 could be determinant
in the development of necroinflammation and fibrosis in
the liver [68].
Moreover, patients with advanced fibrosis had signifi-
cantly increased CXCL10 plasma levels. The reported data
suggested that in patients with HCV genotype 1 CXCR3-
associated chemokines are promising noninvasive markers
of hepatic fibrosis [69–71].
After liver transplantation (LT) for HCV infection, the
recurrence of liver fibrosis can lead to graft loss and patient
mortality [72]. One, 3, 5, and 7 years after LT, routine proto-
col biopsy was conducted, to evaluate the graft inflammation
and fibrosis. In the first year upon LT, CXCL10 levels were
highly associated with early fibrosis recurrence, regardless
of other risk confounders, suggesting that after LT, CXCL10
is an independent biomarker of recurrent significant fibrosis
for HCV infection [72].
Other papers, too, reported that in CHC, CXCL10 can be
considered a marker of liver fibrosis [73–75].
Moreover, it has been shown that HCV-induced CXCL10
can lead to a raised hepatocyte turnover and the development
of cirrhosis, fibrosis, and HCC [38].
In many HCV patients, circulating CXCL10 is enzymati-
cally processed to produce a CXCL10 antagonist form, intro-
ducing a role for chemokine antagonism during HCV
infection [76–78].
Patients with seronegative “occult HCV infection” (OCI)
are anti-HCV and serum HCV-RNA negative but have viral
RNA in the liver and altered levels of liver enzymes [79]. A
study examined if the rs12979860 polymorphism of IL-28B
and serum CXCL10 levels are different between chronic
and seronegative OCI. The IL-28B CC genotype was signifi-
cantly more prevalent in seronegative OCI (52.5%) than in
CHC (24.6%; P < 0 0001) or healthy controls (32.5%; P =
0 039). Patients with seronegative OCI had significantly
lower mean serum CXCL10 levels than CHC patients [79].
CXCL10 single nucleotide polymorphism rs1439490
G/G was more prevalent in OCI patients (90.3%) than
in CHC patients (74.8%; P = 0 008), suggesting that
CXCL10 rs1439490 G/G is positively associated with OCI
in HCV [80].
CHC is associated with HCV-EHM. Several studies
demonstrated elevated CXCL10 and TNF-α circulating
levels in patients with HCV-associated cryoglobulinemia
(MC+HCV) and raised CXCL10 significantly associated
with the presence of active vasculitis [81], particularly in
the presence of AT [82, 83].
5. HCV Therapy and CXCL10
In the first study, CXCL10 serum levels were significantly
(P < 0 02) higher in patients with chronic hepatitis C
(509 8 ± 365 4 pg/mL, mean ± s d ) than in healthy controls
(30 8 ± 20 0 pg/mL,mean ± s d ). Serum CXCL10 was gradu-
ally reduced by IFN therapy, and after the successful treat-
ment of CHC, circulating CXCL10 reached the same levels
of healthy controls [59, 84].
In 29 HCV genotype 1-infected patients, CXCL10 and
CXCL9 were high and decreased after an antiviral therapy
with a good outcome [85]. The CXCL10 level measured
before starting the antiviral treatment was greater in patients
with HCV who then became nonresponders (NR) to therapy
(P = 0 002), indicating that CXCL10 plasma levels can pre-
dict nonresponsiveness or responsiveness to antiviral therapy
with pegylated IFN (PEG-IFN), in the presence/absence of
ribavirin (RBV) [85].
CHC patients treated with PEG-IFN with sustained viral
response (SVR) had significantly lower pretreatment circu-
lating CXCL10 than NR patients (332.4 vs. 476.8 pg/mL). A
significant decrease of serum CXCL10 was shown in patients
with SVR but not in NR. Pretreatment serum CXCL10 levels
and baseline viral load were reported to be predictive factors
of SVR in HCV genotype 1 patients [86].
Another study investigated circulating CXCL10 in 265
HCV-infected patients, before, during, and after PEG-IFN-
α 2a plus RBV treatment [87]. CXCL10 levels declined after
the therapy, remaining low in patients with a SVR. On the
contrary, at the end of the therapy, CXCL10 plasma levels
rebounded in patients who had detectable HCV RNA. Using
cut-off CXCL10 levels of 150 and 600 pg/mL to predict a SVR
in HCV genotype 1-infected patients gave a specificity and
sensitivity of 81% and 95%, respectively [87].
Another study reported significantly lower CXCL10
levels in patients with a rapid viral response (RVR)
(P < 0 0001) and in patients obtaining a SVR (P = 0 0002)
[88]. In multivariate logistic regression analyses, a low
CXCL10 value independently predicted RVR and SVR. A
baseline cut-off CXCL10 value of 600 pg/mL evidenced a
negative predictive value (NPV) of 79% for patients with
HCV genotype 1, similar to the one obtained using a reduc-
tion in HCV-RNA by at least 2 logs after 12 weeks of therapy
(NPV 86%) [88].
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Thyroid autoimmunity is a frequent side effect of IFN-α
therapy for CHC [89, 90].
By pooling data about HCV-positive patients (with CHC
or HCVAb positivity) and taking as control, the total of
healthy subjects, HBV-infected patients, and sera negative
for HCVAb, a significant increase of the prevalence of
thyroid autoimmune disorders (odds ratio OR = 1 6; 95%
confidence interval CI = 1 4 – 1 9) and of hypothyroidism
(OR = 2 9; 95%CI = 2 0 – 4 1) has been described [90].
Both thyroid autoimmunity and dysfunction are com-
mon side effects of IFN-α therapy for CHC, being thyroid
autoantibodies the main predisposing factor for the devel-
opment of thyroid dysfunctions. A paper evaluated pro-
spectively the thyroid status in patients in treatment with
2 distinct preparations of recombinant IFNs [91]. Most
patients developing thyroid autoimmunity during the IFN
treatment showed a destructive thyroiditis in short tempo-
ral relationship to the appearance of thyroid autoanti-
bodies [91].
Pretreatment mean circulating CXCL10 was significantly
higher in patients who did not develop thyroid antibody pos-
itivity or dysfunctions (Group I) compared to those who
showed the appearance of serum thyroid antibodies and later
clinically overt thyroid dysfunction (Group II). The two
groups had different rates of favourable response to IFN-α
treatment (33 and 90%, respectively) [89].
In a further study, CD8+ cells were increased in the liver
and correlated with inflammation [92]. Patients with CHC
showed high serum concentration of CXCL10/CCL3 (vs.
healthy subjects). After PEG-IFN-α-2b plus RBV therapy,
CCR5(high)/CXCR3(high)-expressing CD8+ cell frequency
raised in the peripheral blood, while CXCL10/CCL3 serum
concentration decreased. The obtainment of viral control
was linked to a rise in CXCR3(high)-expressing CD8+ cells
during the therapy [92].
Another study showed that in patients with CHC, low
levels of intrahepatic and systemic CXCL10 predict a good
first-phase decline of HCV RNA during PEG-IFN and RBV
therapy [93].
In patients with a sufficient first response to PEG-IFN,
RBV ameliorates the kinetics of the early response to therapy
[94], and at 12 hours, serum CXCL10 was higher than that
present in patients treated with PEG-IFN alone (7.6- vs.
3.8-fold; P = 0 01) [94].
Other papers agreed that pretreatment CXCL10 levels
could predict SVR and the early virological response (EVR)
to IFN-α therapy and RBV [95–99].
Serum CXCL10 levels were significantly lower in
responders and are considered a predictor for SVR also in
patients with HCV 4 genotype [100, 101].
In CHC patients treated with PEG-IFN and RBV, IL-28B
gene polymorphisms are strongly associated with SVR [102].
CXCL10 was assessed in the pretreatment serum of 115 NR
and 157 sustained responders. Mean CXCL10 was lower in
sustained responders compared to NR (437 ± 31 vs. 704 ±
44 pg/mL, P < 0 001). The PPV of low CXCL10 levels
(<600 pg/mL) for SVR was 69%, while the NPV of elevated
CXCL10 levels (>600 pg/mL) was 67%. The three IL-28B
genotypes (in particular rs12979860) CC, TT, and CT were
reported in 30%, 21%, and 49% of patients, and the rela-
tive SVR rates were 87%, 39%, and 50%, respectively.
The circulating CXCL10 levels within the IL-28B genotype
groups gave more information regarding the probability of
SVR (P < 0 0001). In patients with CT, CC, and TT geno-
types, a higher SVR rate was reported in those with low
CXCL10 levels versus those with high CXCL10 (CT, 64%
versus 24%; CC, 89% versus 79%; and TT, 48% versus
20%). The combination of IL-28B genotype and pretreat-
ment serum CXCL10 levels leads to a significantly higher
predictive value to discriminate between SVR and nonre-
sponse, especially in non-CC genotypes [102].
A second study confirmed that the occurrence of
SNPs adjacent to IL-28B (rs12979860, rs12980275, and
rs8099917), and CXCL10 below 150pg/mL, independently
predicted the first phase viral decline and RVR, which in
turn independently predicted SVR [103].
Other papers, too, confirmed that CXCL10, in combina-
tion with IL-28B, could be a helpful marker to predict treat-
ment failure in HCV patients [104–107].
The IFN-free direct antiviral agent (DAA) therapy has
changed radically antiviral therapy in HCV infection, so
that a successful treatment can be reached to practically
all patients irrespective of their comorbidity [108]. Actually,
3 classes of DAAs are available, and they differ according to
the specific viral protein they target: NS3/4A protease
inhibitors (voxilaprevir, simeprevir, glecaprevir, grazopre-
vir, and paritaprevir); NS5A inhibitors (ombitasvir, ledipas-
vir, velpatasvir, elbasvir, pibrentasvir, and daclatasvir); and
NS5B polymerase inhibitors that block replication of viral
RNA (dasabuvir and sofosbuvir) [109]. During DAA treat-
ment, the inhibition of HCV replication leads to reversal of
NK cells and phenotypic and functional shifts of CD4 and
CD8 T cells typical of CHC, triggering viral reactivation
in patients with chronic hepatitis B and recurrence of
HCC in some patients with earlier effective cancer treat-
ment [109].
Several centers published the data obtained with novel
DAA therapies in HCV-MCS [“mixed cryoglobulinemia syn-
drome” (MCS)], demonstrating a SVR in 297/313 (95%)
patients, and 85% of them had a complete or partial clinical
response of MCS symptoms. Patients with cryoglobulinemic
glomerulonephritis had a good cure rate (94%). Seventeen/52
(33%) experienced full remission, and 15/52 (29%) had par-
tial remission. Less than 5% of the patients with HCV-MCS
treated with IFN-free DAA therapy required immunosup-
pression [110].
Recently, it has been also reported that baseline circulat-
ing CXCL10 can predict virological response in HCV geno-
type 1 CHC patients treated with telaprevir- (TVR-) based
triple therapy, especially in patients with IL-28B risk allele
[111]. CXCL10 was significantly more elevated in patients
with (median, 570.06 pg/mL; range, 209.66–4297.62), than
in those without (median, 394.64 pg/mL; range, 151.35–
1146.43) (P = 0 001), advanced fibrosis (F3/F4). Further-
more, CXCL10 was significantly higher in patients with
(median, 532.59 pg/mL; range, 151.35–1768.81) than in those
without (median, 355.06 pg/mL; range, 155.53–4297.62)
(P = 0 006) moderate/severe activity (METAVIR score
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A2/A3). CXCL10 correlated with liver fibrosis and inflam-
mation [111].
Danoprevir is a powerful and selective DAA, targeting
the protease activity of HCV NS3/4A [112]. During the treat-
ment with danoprevir, changes in the CXCL10 plasma level
were associated with categorical changes in HCV RNA con-
centration at days 7 and 14. Hepatic inflammation can be
reduced by an effective treatment with a DAA and patients
with an elevated baseline CXCL10 level have a higher first-
phase HCV RNA decline during treatment with an NS3/4A
protease inhibitor [112].
Actual therapeutic strategies are derived from the combi-
nation of PEG-IFN, RBV, and (only for patients with geno-
type 1 infection) a protease inhibitor. HCV treatment is
developing fast from IFN-α-based therapies to IFN-α-free
regimens consisting of DAAs that have an increased efficacy
and tolerability in clinical trials. Virologic relapse after DAA
therapy is a common cause of treatment failure, even if the
reason of such relapse or whether some patients are more
likely to recurrent viremia is still unknown. Circulating
CXCL10 decreases with HCV clearance by DAA therapy.
Another study measured CXCL10 in 428 patients at base-
line, week 1, and week 2 of oral treatment for HCV infection,
suggesting that CXCL10 could be considered a surrogate
marker of the rate of intracellular viral replication complex
decay [113].
Peripheral and liver CXCL10 levels were evaluated in 15
patients administered with TVR/PEG-IFN/RBV, showing
that CXCL10 identified very RVR in patients treated with
DAAs [114].
It was investigated whether the elimination of HCV with
DAAs normalizes the expression of IFN-stimulated genes
and NK cell function, from the liver and blood of 13 HCV-
infected patients who did not respond to treatment with
PEG-IFN and RBV, during treatment with daclatasvir and
asunaprevir [115]. DAA-mediated clearance of HCV was
associated with the loss of intrahepatic immune activation
by IFN-α, indicated by decreased levels of CXCL10 and
CXCL11 and normalization of NK cell phenotype and func-
tion [115].
The treatment of CHCwith DAAs results in a fast decline
in viral load and circulating CXCL10 that were followed by a
SVR [116].
Another paper evaluated the role of the immune system
and miRNA levels in acquiring a SVR after DAA therapy in
CHC patients with/without prior RG-101 (anti-miR-122)
dosing [117]. Twenty-nine patients with HCV genotype 1
(n = 11), 3 (n = 17), or 4 (n = 1) were administered with
sofosbuvir and daclatasvir ± ribavirin. Eighteen patients were
treated earlier with RG-101. All patients had an SVR12.
CXCL10 levels decreased during treatment, but remained
high 24 weeks after the treatment in comparison to healthy
subjects (median 53.82 and 39.4 pg/mL, P = 0 02). The
reported data showed that the effective treatment of CHC
patients with/without prior RG-101 dosing reduces broad
immune activation and normalized miR-122 levels [117].
A paper by Yamagiwa et al. investigated the importance
of pretreatment serum CXCL10 levels and IL-28B genotyp-
ing in predicting SVR to TVR-based triple therapy in patients
with HCV 1 genotype [118]. The median CXCL10 levels were
significantly lower in rapid virologic response (RVR)
(343 pg/mL in RVR vs. 593 pg/mL in non-RVR patients,
P < 0 01) or SVR (359 pg/mL in SVR vs. 566 pg/mL in
non-SVR patients, P < 0 05) in the IL-28B non-TT genotype
group. RVR rates were significantly lower in the group with
higher serum CXCL10 levels (>450 pg/mL). In the non-TT
IL-28B genotype group, RVR and SVR rates were signifi-
cantly lower in the group with higher CXCL10 levels. SVR
rates in the group with lower CXCL10 levels (<450 pg/mL)
raised to 82% for those showing RVR, but decreased to 27%
in the group with higher CXCL10 levels for those not show-
ing RVR. The paper showed that the determination of serum
CXCL10 levels before treatment could be useful to predict an
effective virologic response to TVR-based triple therapy, par-
ticularly in patients with IL-28B non-TT genotype [118].
A study explored the dynamic gene expression profile
of PBMCs collected from 27 HCV-infected patients under-
going DAA therapy [119]. The pretreatment expression
level of IFN-induced protein 44 (IFI44) and CXCL10 cor-
related with the pretreatment expression level of IFN-β.
After DAA treatment, a significant decrease (P < 0 05) in
the expression levels of IFN-β, IFI44, and CXCL10 was
observed in the PBMCs. These data showed that pretreat-
ment activation of IFN-β response is rapidly normalized
after DAA treatment [119].
6. Conclusion
CXCL10 and the other CXCR3 chemokines are chemoattrac-
tants for leukocytes, especially Th1 lymphocytes, and are
involved in the pathogenesis of acute and “chronic hepatitis
C virus (HCV) infection” (CHC).
The combination of the serum level of CXCL10 and SNPs
in IL-28B can identify patients with acute HCV infection
who are most likely to have clearance spontaneously and
those in need of early antiviral therapy.
In CHC, the HCV and intrahepatic production of IFN-γ
drive a raised CXCL10 and CXCL9 expression by sinusoidal
endothelium, and by hepatocytes, and thereby promote the
continuing recruitment of CXCR3-expressing T cells into
the hepatic lobule. CXCL10 plays a key role in the develop-
ment of necroinflammation and fibrosis in the liver paren-
chyma in CHC; furthermore, plasma levels of CXCL10 are
significantly higher in patients with advanced fibrosis. In
MC+HCV patients, increased CXCL10 levels were signifi-
cantly associated with the presence of active vasculitis. Fur-
thermore, in CHC and MC patients, CXCL10 circulating
levels were higher in those with associated AT.
After the successful IFN therapy of CHC, the circulating
CXCL10 levels declined to the same level as in a healthy vol-
unteer. Pretreatment CXCL10 levels were predictive of both
EVR and SVR to IFN-α and RBV and may be useful to eval-
uate candidates for therapy. The occurrence of SNPs adjacent
to IL-28B (rs12979860, rs12980275, and rs8099917), and low
circulating CXCL10, independently predicted the first phase
viral decline and RVR, which in turn independently pre-
dicted SVR.
6 Journal of Immunology Research
Actual therapeutic strategies are derived from the combi-
nation of PEG-IFN, RBV, and (only for patients with geno-
type 1 infection) a protease inhibitor (as telaprevir or
boceprevir). Several molecules are under clinical evaluation
for their potential to bypass the disadvantages of the actual
available treatments [120].
The abovementioned studies underline the importance of
CXCL10 as a marker of HCV clearance and successful ther-
apy in CHC patients.
The above reported data indicate that in HCV-infected
patients, antibodies able to block the interaction between
CCR5/CXCR3 and their ligands could decrease chronic liver
inflammation. Since HCV is not directly cytopathic, if the
migration of nonspecific T cells to the infected liver is
impaired, liver damage will be reduced. This strategy could
be evaluated in patients without a SVR after current standard
treatment [71].
Virtually, some chemokines and their receptors are prog-
nostic tools to predict anti-HCV treatment responses, and if
this could be confirmed, these predictors could be added to
daily clinical practice. Moreover, the blocking of chemokines
(CXCL10) and chemokine receptors (CXCR3) is a therapeu-
tic strategy to be evaluated in the future for nonresponders to
current anti-HCV therapy [71].
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